Search
Nektar Therapeutics
NKTRAdd to Watchlist
69.760USD
-0.890-1.26%
Close 09-11 16:00（ET）
2.38BMarket Cap
LossP/E TTM
After-hours 16:17 (ET)69.500USD-0.245-0.35%
After-hours 16:17 (ET)Nektar Therapeutics (NKTR) Stock Price Target & Forecast
Analyst Rating
Based on 11 analysts giving stock ratings to Nektar Therapeutics in the past month.
Buy
5 Strong Buy
5 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
153.222USD+119.64%
NKTR Analyst Recommendation Trends
In the current month, NKTR has received 5 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. NKTR average Analyst price target in the last month is 153.222.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
5
5
5
5
4
4
4
4
5
4
4
4
3
3
3
3
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11
10
10
10
8
8
8
8
NKTR Analyst Rating for Peer Comparison
Updated: Sep 13, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
8
13
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Ascendis Pharma A/S
ASND
10
10
0
0
0
20
Financial Forecasting
Based on analysts' estimates, NKTR EPS is projected to reach -2.131 in FY2026Q3, following reported EPS of -1.229 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-2.47
-1.59
-1.98
-2.13
-2.74
Actual
-1.77
-1.82
-1.23
--
--
Surprise
+28.29%
-13.83%
+38.08%
--
--
FAQs
What is Nektar Therapeutics's expected revenue for the next quarter?
Nektar Therapeutics's expected revenue is 10.42M.
What is Nektar Therapeutics's price target?
Analysts forecast that Nektar Therapeutics's price target is USD 153.22, with the highest forecast at USD 192.00 and the lowest forecast at USD 80.00.
How have Nektar TherapeuticsNKTR's recent earnings per share performed?
The market expectation was USD -1.23, while Nektar TherapeuticsNKTR's earnings per share (EPS) for the previous quarter was USD -1.82. EPS for the next quarter is expected at USD -2.13.
What is the analyst rating for Nektar Therapeutics?
Based on the ratings of Nektar Therapeutics's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.